| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $58M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Over the last 12 months, insiders at 180 Life Sciences Corp. have bought $0 and sold $0 worth of 180 Life Sciences Corp. stock.
On average, over the past 5 years, insiders at 180 Life Sciences Corp. have bought $101,930 and sold $84,860 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 25,000 shares for transaction amount of $4,700 was made by Woody James N. (Chief Executive Officer) on 2023‑12‑15.
| 2023-12-15 | Sale | Feldmann Marc | director | 25,000 0.3408% | $0.19 | $4,700 | -39.08% | |
| 2023-12-15 | Woody James N. | Chief Executive Officer | 25,000 0.3408% | $0.19 | $4,700 | -39.08% | ||
| 2023-06-01 | STEINMAN LAWRENCE | director | 18,000 0.4949% | $1.23 | $22,068 | -75.14% | ||
| 2023-05-31 | McGovern Jr. Donald A. | director | 10,000 0.2685% | $1.15 | $11,470 | -73.87% | ||
| 2023-05-19 | McGovern Jr. Donald A. | director | 5,000 0.1238% | $1.16 | $5,800 | -71.16% | ||
| 2023-05-18 | Woody James N. | Chief Executive Officer | 40,000 1.0572% | $1.03 | $41,200 | -65.28% | ||
| 2023-05-18 | McGovern Jr. Donald A. | director | 10,000 0.2694% | $1.05 | $10,500 | -65.28% | ||
| 2023-05-18 | Marrone Pamela G | director | 7,082.02 0.1926% | $1.06 | $7,507 | -65.28% | ||
| 2023-05-18 | Pamir Ozan | CFO | 5,162.08 0.1338% | $1.01 | $5,214 | -65.28% | ||
| 2021-12-16 | Vu Quan Anh | COO / Chief Business Officer | 8,000 23.6901% | $3.98 | $31,840 | -69.82% | ||
| 2021-12-10 | Pamir Ozan | Interim CFO | 3,800 10.646% | $3.87 | $14,706 | -69.53% | ||
| 2021-12-10 | Vu Quan Anh | COO / Chief Business Officer | 4,500 12.7049% | $3.90 | $17,550 | -69.53% | ||
| 2021-12-10 | Marrone Pamela G | director | 1,000 2.9681% | $4.10 | $4,100 | -69.53% | ||
| 2021-12-09 | STEINMAN LAWRENCE | director | 5,000 15.7263% | $4.27 | $21,350 | -68.88% | ||
| 2021-12-09 | Woody James N. | Chief Executive Officer | 12,500 39.3157% | $4.27 | $53,375 | -68.88% | ||
| 2021-12-09 | McGovern Jr. Donald A. | director | 25,000 76.0533% | $4.13 | $103,250 | -68.88% | ||
| 2021-12-09 | DeLuca Teresa | director | 12,500 36.6824% | $3.98 | $49,800 | -68.88% | ||
| 2020-12-17 | Sale | KRAUSS MARLENE | 10 percent owner | 16,506 65.4229% | $2.48 | $40,880 | +109.89% | |
| 2020-12-15 | Sale | KRAUSS MARLENE | 10 percent owner | 17,877 81.3034% | $2.40 | $42,905 | +148.54% | |
| 2020-12-14 | Sale | KRAUSS MARLENE | 10 percent owner | 10,000 45.4755% | $2.45 | $24,500 | +143.44% |
| KRAUSS MARLENE | 10 percent owner | 2006858 35.2359% | $1.89M | 0 | 6 | |
| OXFORD ASSET MANAGEMENT LLP | 10 percent owner | 832185 14.6113% | $784,001.49 | 0 | 8 | |
| Feldmann Marc | director | 115497 2.0279% | $108,809.72 | 0 | 1 | |
| Woody James N. | Chief Executive Officer | 66888 1.1744% | $63,015.18 | 4 | 0 | <0.0001% |
| STEINMAN LAWRENCE | director | 48129 0.845% | $45,342.33 | 2 | 0 | <0.0001% |
| McGovern Jr. Donald A. | director | 30099 0.5285% | $28,356.27 | 4 | 0 | <0.0001% |
| Vu Quan Anh | COO / Chief Business Officer | 20500 0.3599% | $19,313.05 | 2 | 0 | |
| Marrone Pamela G | director | 12469 0.2189% | $11,747.06 | 2 | 0 | <0.0001% |
| Pamir Ozan | CFO | 8983 0.1577% | $8,462.96 | 2 | 0 | <0.0001% |
| DeLuca Teresa | director | 5000 0.0878% | $4,710.50 | 1 | 0 |
$8,253,997 | 122 | -53.40% | $7.45M | |
$296,936 | 37 | -18.12% | $5.08M | |
$1,138,733 | 28 | -4.94% | $4.13M | |
$63,749,694 | 24 | -12.24% | $4.36M | |
$960,082 | 17 | -6.29% | $4.08M | |
$1,556,551 | 15 | -25.43% | $5.45M | |
$490,284 | 15 | -19.03% | $5.92M | |
$742,412 | 14 | -50.36% | $6.81M | |
$11,777,042 | 10 | -11.94% | $7.23M | |
180 Life Sciences Corp. (ATNF) | $111,748 | 9 | -47.72% | $5.37M |
$214,493 | 7 | -84.84% | $5.81M | |
$40,324 | 6 | 31.82% | $6.87M | |
$115,514 | 4 | -94.89% | $4.73M | |
$726,438 | 4 | -72.85% | $5.22M | |
$1,057,000 | 3 | 5.27% | $5.47M | |
$14,530 | 3 | 62.23% | $5.91M | |
$4,423 | 2 | 3.27% | $5.22M | |
$739,010 | 1 | 3.33% | $3.99M | |
$1,049,630 | 1 | -74.91% | $4.74M |
| Increased Positions | 5 | +27.78% | 27,477 | +5.97% |
| Decreased Positions | 7 | -38.89% | 459,246 | -99.86% |
| New Positions | 4 | New | 27,451 | New |
| Sold Out Positions | 6 | Sold Out | 452,085 | Sold Out |
| Total Postitions | 16 | -11.11% | 28,126 | -93.88% |
| Anson Funds Management Lp | $270.00 | 4.51% | 225,271 | +225,271 | New | 2024-12-31 |
| Hudson Bay Capital Management Lp | $180.00 | 3% | 150,024 | +150,024 | New | 2024-12-31 |
| Rathbones Group Plc | $84.00 | 1.4% | 69,995 | +69,995 | New | 2024-12-31 |
| Ubs Group Ag | $9.00 | 0.14% | 7,164 | +317 | +4.63% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $8.00 | 0.14% | 6,744 | +4,409 | +188.82% | 2024-12-31 |
| Blackrock, Inc. | $1.00 | 0.01% | 564 | 0 | 0% | 2025-03-31 |
| Ifp Advisors, Inc | $0 | <0.01% | 50 | +50 | New | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 38 | +26 | +216.67% | 2025-03-31 |
| Bank Of America Corp /De/ | $0 | 0% | 16 | +9 | +128.57% | 2024-12-31 |
| Fmr Llc | $0 | 0% | 1 | +<1 | New | 2024-12-31 |